Role of fetuin-A in atherosclerosis associated with diabetic patients

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 12, 2012, Pages 1703-1708

  Singh, Monika ^a   Sharma, Pramod Kumar ^a   Garg, Vipin Kumar ^a   Mondal, Shambhu Charan ^a   Singh, Avnesh Kumar ^a   Kumar, Nikhlesh ^b  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b Divya Jyoti College of Pharmacy   (India)

Author keywords

cardio vascular disease; diabetes mellitus; fetuin A; insulin resistance; vascular calcification

Indexed keywords

CALCIUM; FETUIN A; INSULIN RECEPTOR;

ADIPOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; BONE REMODELING; CALCIUM METABOLISM; DIABETIC PATIENT; DIABETOGENESIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 84869091319     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01561.x     Document Type: Review

References (61)

1. Barclay L, Vega C,. Fetuin-A linked with incident diabetes. J Am Med Assoc 2008; 300: 182-188.
2. Swallow JC, et al,. α2HS-glycoprotein, an antagonist of transforming growth factor-β in vivo, inhibits intestinal tumor progression. Cancer Res 2004; 64: 6402-6409.
3. Szweras M, et al,. α2-HS glycoprotein/Fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002; 277: 19991-19997.
4. Emoto M, et al,. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 873-878.
5. Mehrotra R,. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease. Kidney Int 2007; 72: 137-140.
6. Schafer C, et al,. The serum protein alpha 2-Heremans Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
7. Roos M, et al,. Associations of fetuin-A levels with vascular disease in type-2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol 2010; 9: 9-48.
8. Stefan N, et al,. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006; 29: 853-857.
9. Kalabay L, et al,. Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. BMC Gastroenterol 2007; 7: 15.
10. Yang Z, et al,. Defining the carbohydrate specificities of erythrina corallodendron lectin (ECorL) as polyvalent Galβ1-4GlcNAc (II) > monomeric II > monomeric gal and GalNAc. Chang Gung Med J 2008; 31: 26-43.
11. Park CE, et al,. Xenopus cDNA microarray identification of genes with endodermal organ expression. Dev Dyn 2007; 236: 1633-1649.
12. Olivier E, et al,. Fetuin-B, a second member of the fetuin family in mammals. Biochem J 2000; 350: 589-597.
13. Osawa M, et al,. Haplotype analysis of the human α2-HS glycoprotein (fetuin) gene. Ann Hum Genet 2001; 65: 27-34.
14. Sato H, et al,. Decreased levels of circulating α2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 2007; 46: 1685-1692.
15. Hennige AM, et al,. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 2008; 3: e1765.
16. Reinehr T, Christian LR,. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008; 93: 4479-4485.
17. Brix JK, et al,. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 2010; 95: 4877-4881.
18. Ketteler M, et al,. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833.
19. Gross JL, et al,. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
20. Louisa MV, et al,. The role of epigenetics in the pathology of diabetic complications. Am J Physiol-Renal Physiol 2010; 299: F14-F25.
21. Foggensteiner L, et al,. Management of diabetic nephropathy. J R Soc Med 2001; 94: 210-217.
22. Szeberin Z, et al,. Fetuin-A serum levels in patients with aortic aneurysms of Marfan syndrome and atherosclerosis. Eur J Clin Invest 2011; 41: 176-182.
23. Muendlein A, et al,. Are AHSG polymorphisms directly associated with coronary atherosclerosis? Clin Chim Acta 2012; 413: 287-290.
24. Szeberin Z, et al,. Serum fetuin-A levels inversely correlate with the severity of arterial calcification in patients with chronic lower extremity atherosclerosis without renal disease. Int Angiol 2011; 30: 474-450.
25. Xu Y, et al,. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011; 216: 180-186.
26. Ishibashi A, et al,. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 2010; 17: 925-933.
27. Voros K, et al,. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 2011; 41: 703-709.
28. Rauth G, et al,. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 1992; 204: 523-529.
29. Cintron VJ, et al,. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res 2001; 1: 249-263.
30. Taniguchi MC, et al,. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
31. Song A, et al,. Serum Fetuin-A associates with type-2 diabetes and insulin resistance in Chinese adults. PLoS ONE 2011; 6: e19228.
32. Marin C, et al,. The insulin sensitivity response is determined by the interaction between the G972R polymorphism of the insulin receptor substrate 1 gene and dietary fat. Mol Nutr Food Res 2011; 55: 328-335.
33. Wilson C, et al,. Exercise does not alter subcellular localization, but increases phosphorylation of insulin-signaling proteins in human skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290: E341-E346.
34. Mathews ST, et al,. Fetuin null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 2006; 350: 437-443.
35. Ix JH, et al,. Fetuin-A and incident diabetes mellitus in older persons. J Am Med Assoc 2008; 300: 182-188.
36. Hermans MM, et al,. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72: 202-207.
37. Sharon MM,. Vascular calcification: the three-hit model. J Am Soc Nephrol 2009; 20: 1162-1164.
38. Lim P, et al,. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 2007; 53: 1835-1840.
39. Hussein AN, et al,. Serum Fetuin-A in chronic renal disease patients: contribution to endothelial dysfunction and hemostatic alteration. J Am Sci 2010; 6: 1098-1105.
40. Stenvinkel P, et al,. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392.
41. Burke AP, et al,. Fetuin-A, valve calcification, and diabetes: what do we understand? Circulation 2007; 115: 2464-2467.
42. Lorant DP, et al,. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care 2011; 34: 156-161.
43. Stefan N, et al,. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767.
44. Weikert C, et al,. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118: 2555-2562.
45. Siddiq A, et al,. A synonymous coding polymorphism in the a2-Heremans-Schmid glycoprotein gene is associated with type-2 diabetes in French Caucasians. Diabetes 2005; 54: 2477-2481.
46. Stumvoll M, et al,. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity. Interaction with family history of type 2 diabetes. Diabetes 2002; 51: 137-141.
47. Luczak M, et al,. Chronic kidney disease-related atherosclerosis- proteomic studies of blood plasma. Proteome Sci 2011; 9: 25.
48. Allison MA, et al,. Mitral and aortic annular calcifications are highly associated with systemic calcified atherosclerosis. Circulation 2006; 113: 861-866.
49. Carrero JJ, et al,. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med 2008; 263: 302-312.
50. Odamaki M, et al,. Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 2005; 68: 2915-2915.
51. Kon V, et al,. Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 2011; 7: 45-54.
52. Aronson D, Rayfield EJ,. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1.
53. Mori K, et al,. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol 2007; 66: 246-250.
54. Smith RE, et al,. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2011; 10: 1093.
55. Coen G, et al,. Cardiac calcifications: fetuin-A and other risk factors in hemodialysis patients. ASAIO J 2006; 52: 150-156.
56. Westenfeld R, et al,. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007; 17: 124-128.
57. Danesh J, et al,. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
58. Beckman JA, et al,. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2581.
59. Creager MA, et al,. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108: 1527-1532.
60. Dai X-H, et al,. Protective role of α2HS-Glycoprotein in HBV-associated liver failure. Int J Mol Sci 2011; 12: 3846-3856.
61. Dokken BB,. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes Spectr 2008; 21: 160-165.